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Abstract Kanamycin antibiotic was radiolabeled successfully with radioisotope technetium-99m for the potential use as 
radiopharmaceuticals for infection imaging. 99mTc-kanamycin complexes was prepared 93 % radiochemical purities by 
direct labelling using 5 mg kanamycin and 30 µg SnCl2. The reaction occurred at alkaline condition (pH=9) and under 
room temperature for 30 min to achieve high radiochemical purity. Radiochemical purity and stability of 99mTc-kanamycin 
was determined by ascending paper chromatography using Whatman 3 paper as the stationary phase, and acetone as the 
mobile phase to separate the radiochemical impurities in the form of 99mTc-pertechnetate. While impurities in the form of 
99mTc-reduced were separated using the stationary phase ITLC-SG and 0.5 N NaOH as mobile phase. This study aimed to 
determine biological characteristic of 99mTc-kanamycin radiopharmaceutical. In vitro cell studies showed that the change 
of kanamycin structure after labeling with technetium-99m did not give a specific influence to the potency of kanamycin 
as an antibiotic. In addition on uptake study, a significantly higher uptake of 99mTc-kanamycin with S. aureus than E. coli. 
Biodistribution of 99mTc-kanamycin complexes was studied on normal and infection mice at 15, 30, 60 and 120 min post-
injections. The biodistribution of 99mTc-kanamycin in infection mice showed that the complex accumulated in the infection 
sites. These results show that 99mTc-Kanamycin radiopharmaceutical have a potential application for infection diagnosis. 
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1. INTRODUCTION 
According to the  Global  Report 2012 
data, infectious diseases were responsible for 
the death of almost 9 million people worldwide 
in every year, and many of them are children 
under five years old (WHO, 2012). Those 
infection deaths occur because of late 
identifications of main infections which occur 
in very deep parts of the body (deep-seated 
infection). Early detection and determination 
of the infection location are required. Nuclear 
medicine come to give solution for infection 
disease management. The development of new 
radiopharmaceuticals which are able to 
differentiate between inflammatory and 
infectious with high specificity are required. 
Certain studies show that radiolabeled 
antibiotics or antimicrobial peptides are 
capable to distinguishing between infective 
and non-infective inflammations (Akhtar et al, 
2012; Doroudi et al., 2014; Ebenhan et al., 2014; 
Fazli et al, 2012; Ilem-Özdemir, 2013; Ilem-
Ozdemir et al., 2014; Mirshojaei et al., 2010; 
Sanad, 2014).  
Kanamycin is an antibiotic belonging to the 
aminoglycosides that act by binding to the 
bacterial ribosome, thereby inhibiting protein 
synthesis and generating errors in the translation 
of the genetic code (Magnet, 2005). Its nature as 
a broad-spectrum antibiotic allows it to bind to 
Gram-negative and Gram positive bacteria. 
Kanamycin is used to treat infections when 
penicillin or other less toxic drugs cannot be used. 
Infections treated include: bone, respiratory tract, 
skin, soft tissue, and abdominal infections, 
complicated urinary tract infections, endocarditis, 
septicaemia, and enterococcal infections (Roohi 
et al, 2006). Kanamycin has several electron 
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donor fungctional groups such as –NH2, -OH 
and –O- that can form bonds with technetium-
99m. 99mTc-kanamycin (Fig. 1) labeling 
studies have been carried out in the previous 
research by direct labeling method with the 
result of labeling efficiency of about 93 % (E 
M Widyasari et al, 2015). Besides study of 
physico-chemical characteristics of 99mTc-
kanamycin have also been studied. In this 
paper biological evaluation (in vitro and in 
vivo study) of 99mTc-kanamycin were studied 
in detail experimental. 
 
Fig. 1. Chemical structure predictions of 99mTc-
kanamycin 
2. MATERIALS AND METHODS 
2.1 Materials and equipments 
The materials used to carry out in this 
research were kanamycin sulphate from Meiji 
and stannous chloride dihydrate purchased 
from Sigma Aldrich Company. All other 
chemicals were of reagent grade and were used 
without further purification. 99Mo/99mTc 
generator was obtained from BATAN 
Technology. Paper chromatography analysis 
was carried out with Whatman no. 3 paper 
chromatography and ITLC-SG (Agilent). The 
white mice (Mus musculus) were obtained by 
cultivation alone and biodistribution studies were 
performed with mus musculus mice that has 
infected with Staphylococcus aureus and 
Escherichia coli bacteria. The Animal Ethics 
Committee (KEPPH) of BATAN gave approval 
for the animal experiments. 
The equipment used in this experiment 
consists of dose calibrator (Victoreen), vortex 
mixer, single channel analyzer (Ortec), and paper 
chromatography apparatus. 
2.1 Radiolabeling and quality control 
techniques 
The preparations procedure for 99mTc-
kanamycin and the paper chromatography 
analysis conditions are as follows. 0.9 mL of 
saline containing (99mTcO4- ± 2-5 mci) was added 
to a kanamycin wet kit containing 5 mg/mL of 
kanamycin and 30 µg of stannous chloride 
dehydrate. The mixture was kept at room 
temperature for 30 min. The determination of the 
radiochemical purity of 99mTc-kanamycin was 
performed using Whatman no. 3 paper as the 
stationary phase and acetone as the mobile phase 
to separate of 99mTc-pertechnetat (99mTcO4-). 
Meanwhile, to separate the impurity of 99mTc-
reduced (99mTcO2), ITLC-SG was used as the 
stationary phase and 0.5 N NaOH as a mobile 
phase. The chromatograms were dried in oven at 
80oC for five minutes, and then paper was cut 
every 1 cm piece and measured using single-
channel analyser (SCA) with detector NaI(Tl). 
2.3 In vitro cell studies 
Binding of 99mTc-kanamycin to bacteria was 
assessed by the method described previously 
(Sugiharti et al., 2015). Briefly, 2 ml of saline 
containing approximately 1 × 107 colony forming 
units (CFU) per ml viable S. aureus or E. coli was 
transferred to a centrifuge tube. Then, 0.1 ml 
99mTc-kanamycin were added. The mixture was 
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incubated for 1, 3, 5 and 24 h in waterbath 
shaker at 37oC and 120 rpm. Thereafter to each 
vial was added 500 µL TCA 10 % b/v and then 
the vials were centrifuged for 5 min. The 
supernatant was separated, and the 
radioactivity in the bacterial pellet was gently 
re-suspended in 1ml of PBS and re-centrifuged 
as above. The supernatant was sparated and the 
radioactivity in the bacterial pellet and 
supernatant were determined by Single 
Channel Analyzer (SCA). The radioactivity 
related to bacteria was expressed in percent of 
the added 99mTc activity bounded to viable 
bacteria in regard to total 99mTc (supernatant 
and pellet). Na99mTcO4 was used as control. 
2.4 Pharmacokinetics studies 
The blood clearance study was performed 
in Swiss mice (normal mice) weighing about 
40-50 g, after administering 400 µCi/0.4 ml of 
labeled product intravenously through the tail 
vein. At time intervals of 5 min, 15 min, 30 
min, 45 min, 1 h, 2 h, 3h, 4 h, 5h, 24h and 30 
h, about one drop blood was withdrawn from 
the tail vein of the animal. The samples were 
weighed accurately to the second decimal 
place in grams and radioactivity was measured 
using a SCA. The data were expressed as 
percent administered dose per gram of blood at 
each time interval. 
2.5 Biodistribution studies 
Biodistribution studies was prepared on 
three groups animal experiments, which 
involve group of normal mice, group of 
infected mice with E. coli, and group of 
infected mice with S. aureus. Each group 
consisted of 12 mice were divided in four time 
intervals i.e. 15, 30, 60 and 120 min after 
injection and each time interval consisting of 
three mice. To prepare infected model, the day 
before each study, Swiss mice with weighing 40-
50 g were infected by injecting 0.1 ml of saline 
containing 2 × 106 CFU bacteria into right thigh 
muscle. 24 h later, they were injected with 0.1 ml 
(100 µCi) of 99mTc-kanamycin via the tail vein. 
At 15, 30, 60 and 120 min post administration, 
mice were sacrificed and organs of interest were 
collected, weighed and radioactivity was 
measured with SCA. Radioactivity accumulated 
in each organ was expressed as percent 
administered dose per gram of tissue. 
3. RESULTS AND DISCUSSION 
In this studies labeling 99mTc-kanamycin 
was prepared by direct labeling method. In the 
previous research, 99mTc-kanamycin labeling 
studies have been carried out by the indirect 
method using pyrophosphate as a co-ligand with 
the result of labeling efficiency of above 95% 
(Sugiharti et al., 2015; E M Widyasari, 2013a; E 
M Widyasari, 2013b; E M Widyasari et al., 2015). 
However, the presence of radiochemical 
impurities in the form of 99mTc-pyrophosphate in 
this indirect labeling method may interfere 
imaging results. The accumulation of 99mTc-
pyrophosphate in the bone made it difficult to 
distinguish between an infection of the bone and 
the uptake of 99mTc-pyrophosphate. 
Radiochemical purity (RCP) was assessed 
by a combination of ascending paper 
chromatography and instant thin layer 
chromatography on silica gel. In paper 
chromatography (whatman 3) as stationary phase 
and aceton as the solvent, impurities 99mTcO4- 
migrated with the front (Rf=1) while 99mTc-
kanamycin and reduce/hydrolysed 99mTc remined 
at the origin (Rf=0). In ITLC-SG chromatography 
using NaOH 0.5 N as the solvent, impurities 
reduce/hydrolysed 99mTc remined at the origin, 
whereas 99mTc-kanamycin and 99mTcO4- moved 
with the front. The mean RCP of the 99mTc-
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kanamycin was 92.31 ± 1.74%. As a 
radiopharmaceutical to be administered 
intravenously it is necessary to test its stability 
in plasma. The result of stability test 99mTc-
kanamycin in the plasma showed that up to 4 
hours of incubation (Fig. 2), 99mTc-kanamycin 
is still providing a RCP > 90 %. This shows 
that plasma environment does not outlining the 
bond between technetium-99m and kanamycin 
(Eva Maria Widyasari, 2015). 
 
Fig. 2. 99mTc-kanamycin stability in plasma 
From in vitro study, that has been 
reported before (Sugiharti et al., 2015), 
showed the change of kanamycin structure 
after labeling with technetium-99m did not 
give a specific influence to the potency of 
kanamycin as an antibiotic. In vitro bacteria 
uptake using Staphylococcus aureus (S. 
aureus) and Escherichia coli (E. coli) bacteria 
showed that decreased uptake of 99mTc-
kanamycin as a function of incubation time 
was observed (Fig. 3 and Fig. 4). 99mTc-
kanamycin had optimal uptake at 1 h post 
incubation and reached a high S. aureus and E. 
coli bacteria uptake. S. aureus bacteria uptake 
(53.00 ± 0.30 %) was greater than E. coli 
(36.99 ± 1.40 %). This was due to differences 
in the composition of the cell wall in bacteria 
S. aureus with E. coli. As the gram-positive 
bacteria (S. aureus) cell wall consists of 
peptidoglycan whereas Gram-negative bacteria 
(E. coli) cell wall consists of peptidoglycan and 
lipopolysaccharide. That difference caused S. 
aureus more susceptible to kanamycin so S. 
aureus bacteria uptake was greater than E. coli. 
These results are also reliable with previous 
research that has been done by S. Roohi, et.al 
which has proved that 99mTc-kanamycin has in- 
vivo S.aureus uptake in the range of 40-50 % 
(Roohi et al., 2006). 
 
Fig. 3. Effect of incubation time on E. coli and S. aureus 
bacteria uptake of 99mTc-kanamycin and 99mTcO4- 
99mTc-kanamycin as a radiopharmaceutical 
for detection infection is not accumulated in the 
normal organ or tissue and rapidly excreted from 
the body. The result of biodistribution of 99mTc-
kanamycin are shown in Table 1 and 2. The 
results were expressed as the percent uptake of 
injected dose per gram of tissue (%ID/g) and at 
least in 3 mice. As described in the Table 1 and 
Table 2, high uptakes were found in blood, 
kidneys and liver at 15 min post injection. The 
high accumulation in the liver was probably due 
99mTc-kanamycin metabolised by hepatobiliary 
rute i.e. intestine, liver, spleen and will be 
excreted through the feses. Considerable 
accumulation in the liver instead of caused by 
99mTc-reduce (radiochemical impurities) because 
it based on the result of stability test, 99mTc-
kanamycin fairly stable in plasma. Besides the 
higest accumulation in the kidney showed that 
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99mTc-kanamycin rapidly excreted from the 
body to urine. Specific accumulation in 
infected thigh muscles as indicated by T/NT 
rations, was 1.81 and 2.66 at 15 and 30 min 
post injection in E.coli infected mice. Whereas in 
S. aureus infected mice was 2.56 and 1.85 at 15 
and 30 min post injection. 
 
Table 1. Biodistribution of 99mTc-kanamycin in E. coli infected mice at 15, 30, 60 and 120 min post-injection. 
Tissue 15 min 30 min 60 min 120 min 
Infected muscle 2.49% ± 0.42% 1.14% ± 0.62% 0.33% ± 0.04% 0.31% ± 0.16% 
Normal muscle 1.38% ± 0.59% 0.43% ± 0.10% 0.33% ± 0.06% 0.17% ± 0.06% 
Blood 4.98% ± 1.39% 2.14% ± 0.97% 0.77% ± 1.10% 0.59% ± 0.43% 
Liver 8.23% ± 0.72% 5.59% ± 1.44% 4.71% ± 0.50% 4.34% ± 1.10% 
Kidneys 36.65% ± 3.45% 31.71% ± 6.29% 32.67% ± 2.41% 24.14% ± 9.24% 
Heart 2.74% ± 1.16% 1.08% ± 0.45% 0.66% ± 0.07% 0.40% ± 0.08% 
Lung 7.17% ± 1.98% 2.84% ± 1.30% 1.86% ± 0.12% 1.21% ± 0.31% 
Stomach 3.33% ± 1.23% 1.29% ± 0.46% 0.89% ± 0.13% 0.57% ± 0.15% 
 
Table 2. Biodistribution of 99mTc-kanamycin in S. aureus infected mice at 15, 30, 60 and 120 min post-injection 
Tissue 15 min 30 min 60 min 120 min 
Infected muscle 2.84% ± 0.89% 0.90% ± 0.02% 0.69% ± 0.01% 0.35% ± 0.11% 
Normal muscle 1.11% ± 0.31% 0.49% ± 0.01% 0.35% ± 0.03% 0.20% ± 0.01% 
Blood 5.65% ± 0.40% 2.60% ± 0.41% 2.49% ± 0.20% 1.59% ± 0.20% 
Liver 8.94% ± 2.65% 8.93% ± 0.94% 8.91% ± 1.07% 6.31% ± 0.75% 
Kidneys 44.76% ± 9.31% 41.92% ± 1.20% 59.95% ± 2.99% 48.43% ± 2.57% 
Heart 2.61% ± 0.02% 1.22% ± 0.09% 0.95% ± 0.00% 0.55% ± 0.07% 
Lung 5.90% ± 0.18% 2.21% ± 0.75% 2.25% ± 0.04% 1.06% ± 0.26% 
Stomach 2.93% ± 0.34% 1.87% ± 0.04% 1.27% ± 0.11% 0.86% ± 0.25% 
 
Radiopharmaceuticals for diagnosis 
should be quickly accumulated in the target 
organs and rapidly clearance from blood. 
Blood clearance test results of 
radiopharmaceutical 99mTc-kanamycin 
showed 5 minutes after injection of complex 
activity remains only 4.44% and then decreased 
to 1.38%, 0.73%, 0.63%, 0.60%, 0.59%, 0.21%, 
and 0.16% respectively at 1,  2 , 3, 4, 5, 24 to 30 
hours (Fig. 5). The decline complex in the blood 
is due in part already excreted complex through 
the kidneys and partly distributed to the target 
organs of infected muscle and other organs. 
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Fig 5. Blood clearance 99mTc-kanamycin in normal mice
Whole body imaging studies with a 
gamma camera are infected mice was 
presented in Fig. 6. From this result show that 
99mTc-kanamycin was accumulated in the liver 
and kidney same as biodistribution test results. 
Moreover from this figure also shown that the 
accumulation of 99mTc-kanamycin in the thigh 
infected by S. aureus (left thigh) are more higer 
than normal thigh (right thigh). So can be 
concluded that 99mTc-kanamycin specific and 
sensitive to infections caused by bacteria. 
 
 
  Poling   1 hour post injection  3 hour post injection 
Fig. 6. Whole body gamma camera image of infected mice (S. aureus) injected with 99mTc-kanamycin
4. CONCLUSION AND REMARKS 
Kanamycin was successfully labeled 
with 99mTc by direct methods. In vitro study 
showed the change of kanamycin structure 
after labeling with technetium-99m did not 
give a specific influence to the potency of 
kanamycin as an antibiotic. In vitro bacteria 
uptake showed that decreased uptake of 99mTc-
kanamycin as a function of incubation time. The 
result of biodistribution and imaging study show 
that 99mTc-kanamycin quite specific and sensitive 
detection infections caused by bacteria. 
4.90%
2.73%
2.21%
1.82%
1.38%
0.70%
0.73%
0.63%
0.60%
0.59% 0.21% 0.16%
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
0 5 10 15 20 25 30 35
%
ID
/g
Time (hour)
Indonesian Journal of Physics and Nuclear Application, Vol. 2, No. 1, February 2017 
40 
 
REFERENCES 
Akhtar, M. S., Imran, M. B., Nadeem, M. A., 
& Shahid, A. (2012). Antimicrobial 
peptides as infection imaging agents: 
better than radiolabeled antibiotics. 
International Journal of Peptides, 2012, 
965238. 
http://doi.org/10.1155/2012/965238 
Doroudi, A., Erfani, M., Kamali-Moghaddam, 
M., Saadati, S. M., Ahmadi, F., Kiasat, 
A., … Meghdadi, H. (2014). Sensetivity 
and specificity of 99mTc-UBI29-41 and 
67Ga-citrate scintigraphy imaging to 
discriminate infection lesion induced by 
Staphylococcus aureus and sterile 
inflammation lesion induced by 
Carrageenan in foot ’ s rat. IOSR Journal 
of Pharmacy, 4(11), 37–43. 
Ebenhan, T., Zeevaart, J. R., Venter, J. D., 
Govender, T., Kruger, G. H., Jarvis, N. V, 
& Sathekge, M. M. (2014). Preclinical 
Evaluation of 68Ga-Labeled 1,4,7-
Triazacyclononane-1,4,7-Triacetic Acid-
Ubiquicidin as a Radioligand for PET 
Infection Imaging. Journal of Nuclear 
Medicine : Official Publication, Society 
of Nuclear Medicine, 55(2), 1–7. 
http://doi.org/10.2967/jnumed.113.1283
97 
Fazli, A., Salouti, M., Ahmadi, G., Mirshojaei, 
F., & Mazidi, M. (2012). Radiolabeling of 
Ceftriaxone with 99mTc as a Targeting 
Radiopharmaceutical for Staphylococcus 
Aureus Detection in Mouse Model, 9(2), 
103–110. 
Ilem-Özdemir, D., Aşikoǧlu, M., & Özkiliç, 
H. (2013). Radiolabeling, quality control 
and kit formulation of a new 99mTc-
labeled antibiotic: 99mTc-doxycycline 
hyclate. Journal of Radioanalytical and 
Nuclear Chemistry, 298(3), 1635–1642. 
http://doi.org/10.1007/s10967-013-2547-
2 
Ilem-Ozdemir, D., Asikoglu, M., Ozkilic, H., 
Yilmaz, F., Hosgor-Limoncu, M., & 
Ayhan, S. (2014). 99mTc-Doxycycline 
hyclate: A new radiolabeled antibiotic for 
bacterial infection imaging. Journal of 
Labelled Compounds and 
Radiopharmaceuticals, 57(1), 36–41. 
http://doi.org/10.1002/jlcr.3135 
Magnet, S., & Blanchard, J. S. (2005). Molecular 
Insights into Aminoglycoside Action and 
Resistance Molecular Insights into 
Aminoglycoside Action and Resistance. 
Chemical Reviews, 105(2), 477–498. 
http://doi.org/10.1021/cr0301088 
Mirshojaei, S. F., Erfani, M., Sadat-Ebrahimi, S. 
E., Talebi, M. H., Haj, F., Abbasi, H., & Ir, 
W. S. (2010). Freeze-Dried Cold Kit for 
Preparation of 99mTc-Ciprofloxacin As an 
Infection Imaging Agent Archive of SID. 
Iran J Nucl Med, 18(2), 45–51. 
Roohi, S., Mushtaq, A., Jehangir, M., & Malik, 
S. A. (2006). Synthesis, quality control and 
biodistribution of 99mTc- Kanamycin. 
Journal of Radioanalytical and Nuclear 
Chemistry, 267(3), 561–566. 
http://doi.org/10.1007/s10967-006-0087-8 
Sanad, M., & Borai, E. (2014). Performance 
characteristics of biodistribution of 99mTc-
cefprozil for in vivo infection imaging. 
Journal of Analytical Science and 
Technology, 5(1), 32. 
http://doi.org/10.1186/s40543-014-0032-3 
Sugiharti, R. J., Widyasari, E. M., Nur, I., Dewi, 
U., Langsung, P., Bakteri, T., & Escherichia, 
D. A. N. (2015). IN-VITRO STUDY OF 
KANAMYCIN LABELED WITH 
TECHNETIUM-99m BY DIRECT 
METHOD TO Staphylococcus aureus AND 
Escherichia coli. In Proceedings of the 
Scientific Meeting of radioisotopes , 
Radiopharmaceuticals , Cyclotron and 
Nuclear Medicine 2015 (pp. 34–38). 
Bandung. 
WHO. (2012). Global report for research on 
infectious diseases of poverty., 1–184. 
http://doi.org/9789241564489 
Widyasari, E. M., Sriyani, M. E., Halimah, I., 
Wongso, H., Wibawa, T. H. A. I., & Sidik, 
A. (2015). EVALUATION OF 
PHARMACEUTICAL ASPECTS AND IN-
Eva Maria Widyasari, Iim Halimah, Rizky Juwita Sugiharti, Maula Eka Sriyani, Isti Daruwati , Iswahyudi, Epy Isabela 
and Witri Nuraeni, Biological Evaluation of 99mTc-Kanamycin for Infection Imaging 
41 
 
VITRO ANTIBACTERIAL ACTIVITY 
OF 99MTc-KANAMYCIN 
DIAGNOSTIC KITS. Ganendra Journal 
of Nuclear Science and Technology, 
18(1), 1–9. 
Widyasari, E. M., Sriyani, M. E., & Nuraeni, 
W. (2015). STABILITY OF 99mTc-
KANAMYCIN 
RADIOPHARMACEUTICAL FOR 
DETECTION OF INFECTION. In 
Proceedings of the Nuclear Research and 
Management Device Seminar (pp. 9–10). 
Widyasari, E. M., Sriyani, M. E., Wibawa, T. 
H. A., & Nuraeni, W. (2015). Preparation 
of 99mTc-Kanamycin using a Direct 
Labeling Method. Atom Indonesia 
Journal, 41(3), 131–137. 
Widyasari, E. M., Wibawa, T. H. A., & 
Nuraeni, W. (2013). 
PHYSICOCHEMICAL 
CHARACTERISTICS OF THE 
KANAMYCIN-LYOPHILIZED KIT. 
Indonesian Journal of Nuclear Science 
and Technology, 43(2), 117–126. 
Widyasari, E. M., & Zainuddin, N. (2013). 
The Labeling of Kanamycin Using 
Radionuclide of Technetium As An 
Agent for Early Detection of Infectious 
Deseases. A Scientific Journal for The 
Applications of Isotopes and Radiation, 
9(2), 91–100. 
